TY - JOUR A2 - Galani, Vasiliki AU - Zhang, Hui AU - Mehmood, Khalid AU - Jiang, Xiong AU - Yao, Wangyuan AU - Iqbal, Mujahid AU - Li, Kun AU - Tong, Xiaole AU - Wang, Lei AU - Wang, Meng AU - Zhang, Lihong AU - Nabi, Fazul AU - Rehman, Mujeeb Ur AU - Li, Jiakui PY - 2018 DA - 2018/03/20 TI - Effect of Icariin on Tibial Dyschondroplasia Incidence and Tibial Characteristics by Regulating P2RX7 in Chickens SP - 6796271 VL - 2018 AB - Tibial dyschondroplasia (TD) is a disease of rapid growing chickens that occurs in many avian species; it is characterized by nonvascular and nonmineralized growth plates, along with tibia bone deformation and lameness. Icariin is widely used to treat bone diseases in humans, but no report is available regarding the effectiveness of icariin against avian TD. Therefore, this study was designed to determine its effect against TD. For this purpose, a total of 180 broiler chicks were distributed into three groups including control, TD, and icariin group. Control group was given a standard normal diet, while TD and icariin groups received normal standard diet containing 50 mg/kg thiram to induce TD from days 3 to 7 after hatch. After the induction of TD, the chicks of icariin group were fed with standard normal diet by adding 10 mg/kg icariin in water. Then morphological and production parameters analysis of tibial bone indicators, physiological index changes, and gene expression were examined. The results showed that icariin administration not only decreased the mortality but also mitigated the lameness and promoted the angiogenesis, which diminished the TD lesion and significantly increased the expression of P2RX7 (P<0.05) in TD affected thiram induced chicks. In conclusion, present findings suggest that icariin has a significant role in promoting the recovery of chicken growth plates affected by TD via regulating the P2RX7. Our findings reveal a new target for clinical treatment and prevention of TD in broiler chickens. SN - 2314-6133 UR - https://doi.org/10.1155/2018/6796271 DO - 10.1155/2018/6796271 JF - BioMed Research International PB - Hindawi KW - ER -